HCA Healthcare, Inc. — 2020 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020. Although the request identifies 2020 Q4, this is an annual filing; the supplied filing text does not provide a clear standalone fourth-quarter income statement or cash flow summary. Unless noted, amounts are in U.S. dollars.
Business context
HCA operated 185 hospitals, 121 freestanding surgery centers and 21 endoscopy centers across 20 U.S. states and England. Its results were materially affected by COVID-19, including reduced elective procedures and patient visits, particularly in the first half of 2020.
Key financial metrics
| Metric | 2020 | 2019 | Change or context |
|---|---|---|---|
| Revenue | $51.533 billion | $51.336 billion | Up 0.4%; same-facility revenue down 0.1% |
| Income before income taxes | $5.430 billion | $5.244 billion | Up 3.6%; 10.5% of revenue in 2020 |
| Net income attributable to HCA | $3.754 billion | $3.505 billion | Up 7.1%; diluted EPS was $10.93 vs. $10.07 |
| Adjusted segment EBITDA | $10.037 billion | $9.857 billion | Up 1.8%; approximately 19.5% of revenue in 2020 |
| Operating cash flow | $9.232 billion | $7.602 billion | Up $1.630 billion |
| Capital expenditures, excluding acquisitions | $2.835 billion | $4.158 billion | Reduced during the pandemic |
| Cash and cash equivalents | $1.793 billion | $621 million | At year-end |
| Total debt | $31.004 billion | $33.722 billion | Down $2.718 billion; average debt cost was 5.0% vs. 5.3% |
| Working capital | $3.629 billion | $3.439 billion | At year-end |
Cash flow from operations less reported capital expenditures was approximately $6.397 billion in 2020; this is a simple calculation and excludes acquisitions and other investing items. Management attributed much of the operating-cash-flow improvement to favorable working-capital changes, including higher accounts payable and accrued expenses and collections of receivables.
Material changes and unusual items
- Equivalent admissions fell 9.2% and admissions fell 4.7%. Emergency-room visits declined 18.7%; outpatient surgeries fell 12.6% and inpatient surgeries 7.8%.
- Revenue per equivalent admission rose 10.5%, partly offsetting lower volume. Management attributed volume weakness primarily to pandemic-related restrictions and concerns about exposure to the virus.
- Interest expense declined $240 million to $1.584 billion, reflecting lower average debt and interest rates. HCA issued $2.7 billion of 3.50% senior notes due 2030 and redeemed $3.0 billion of higher-coupon notes, recording a $295 million pretax debt-retirement loss.
- 2020 earnings included a $60 million employee-retention payroll tax credit, $124 million of revenue related to prior-period settlements or transaction-price resolutions, and a $112 million reduction in professional-liability provisions based on updated actuarial information. These items affect comparisons of underlying performance.
- Operating cash flow benefited from $1.366 billion of favorable working-capital changes. HCA also deferred $688 million of employer Social Security taxes, with repayment due in 2021 and 2022.
Outlook, liquidity and risks
- Management expected operating cash flow, available credit facilities and anticipated debt-market access to meet liquidity needs for the next 12 months. Planned 2021 capital expenditures were approximately $3.7 billion.
- HCA received about $4.4 billion in accelerated Medicare payments and $1.8 billion in Provider Relief Fund distributions during 2020, then returned or repaid approximately $6.1 billion in the fourth quarter. A further $83 million related to partnership entities was recorded as a refund liability and expected to be returned in 2021.
- At December 31, 2020, HCA reported $31.004 billion of debt and substantial leverage. Its debt agreements include financial and operating covenants; $3.671 billion of borrowings were LIBOR-based. The $2.0 billion 364-day term-loan facility was terminated in January 2021.
- In February 2021, HCA reinstated its quarterly dividend, declaring $0.48 per share, and resumed share repurchases; the board authorized an additional $6 billion, bringing total authorization to $8.8 billion. Future distributions and repurchases remain subject to board decisions, liquidity and debt agreements.
- Principal risks include further COVID-19 disruption, staffing shortages and higher labor costs, payer and government reimbursement changes, patient-account collectability, regulatory investigations and litigation, professional-liability claims, cybersecurity, and HCA’s concentration in Florida and Texas. Those two states accounted for 49% of 2020 revenue.
Important facts for investors to verify
- Whether patient volumes and elective-procedure activity recovered after year-end, and whether revenue-per-admission increases can persist without comparable volume recovery.
- How much of the 2020 earnings and cash-flow improvement reflects recurring operations versus prior-period adjustments, liability reserve releases, tax credits, deferred payroll taxes and working-capital movements.
- The timing and terms of debt maturities, covenant headroom, refinancing needs and transition away from LIBOR; the filing lists $5.872 billion of maturities in 2025.
- Whether the $3.7 billion 2021 capital-spending plan and resumed shareholder returns remain consistent with debt reduction and liquidity priorities.
- Potential changes to Medicaid supplemental payments, including Texas waiver payments of $599 million in 2020, and the status or outcome of the disclosed Texas Medicaid-related qui tam lawsuit.